Patent Expiry

Patent/Exclusivity Expiry: EDARBI

Drug
EDARBI

Other upcoming events for TAK

Phase 2 StartPhase 2 Start: A Phase 2 Open-label Trial to Evaluate the Efficacy and Safety of Rusfertide in Japanese Patients Wi
Phase 2 StartPhase 2 Start: A Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase 2 Trial to Evaluate the Safety an
Phase 3 ReadoutPhase 3 Topline: An Open-label, Multicenter Clinical Study on The Long-term Safety and Efficacy of Multiple Treatment
Phase 3 ReadoutPhase 3 Topline: An Open-Label, Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Intravenous (
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mez

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Patent/Exclusivity Expiry: EDARBI — TAK Patent Expiry | BioSniper